Literature DB >> 28082046

A comprehensive evaluation for the treatment of lupus nephritis.

Evangelia Zampeli1, Dennis M Klinman2, M Eric Gershwin3, Haralampos M Moutsopoulos4.   

Abstract

Systemic lupus is the prototypic human autoimmune disease. It is a kaleidoscope of autoreactivities, with clear indications of both a genetic and environmental basis. Indeed, it is a disease that can manifest in virtually every tissue and organ and can also be found spontaneously in a number of animal species, including dogs, cats and horses. Moreover, there are multiple murine models of lupus, the first of which, New Zealand Black (NZB) mice, were discovered in 1959. Despite an enormous effort from scientists in multiple disciplines, the etiology of lupus remains elusive and the introduction of new therapies has been disappointing. Fortunately, significant advances have occurred to help patients through the general principles of internal medicine, including antibiotics, dialysis, and of course use of steroids and immunosuppressive agents. However, the magic bullet has yet to be discovered. One of the major causes of morbidity in lupus remains lupus nephritis and there has been significant effort and encouragement in understanding the pathogenesis, renal histologic classification, and use of therapeutic protocols to induce and sustain remission of lupus nephritis. Indeed, the first use of evidence-based clinical trials in lupus was initiated by Dr. Alfred D. Steinberg at NIH in pioneering studies involving either oral or intravenous pulses of cyclophosphamide, azathioprine or corticosteroids alone and/or some combination. Cyclophosphamide intravenously proved to be superior and the use of cyclophosphamide in combination with methylprednisolone remained the standard protocol for the treatment of lupus nephritis for decades. Although alternative therapies have been introduced, including mycophenolate mofetil, the use of therapies first pioneered at NIH may still be considered standard of care in the appropriate indications. More targeted therapies are much desired. In this review we provide a comprehensive overview of lupus nephritis and the evolution of clinical treatments.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28082046     DOI: 10.1016/j.jaut.2016.12.011

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  8 in total

Review 1.  Autoimmunity in 2017.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

2.  Suppression of Fli-1 protects against pericyte loss and cognitive deficits in Alzheimer's disease.

Authors:  Pengfei Li; Yan Wu; Eric D Hamlett; Andrew J Goodwin; Perry V Halushka; Steven L Carroll; Meng Liu; Hongkuan Fan
Journal:  Mol Ther       Date:  2022-01-14       Impact factor: 12.910

Review 3.  Revisited Cyclophosphamide in the Treatment of Lupus Nephritis.

Authors:  Xiao-Ying Quan; Hao-Tao Chen; Si-Qin Liang; Chen Yang; Cui-Wei Yao; Yong-Zhi Xu; Hua-Feng Liu; Ning An
Journal:  Biomed Res Int       Date:  2022-05-26       Impact factor: 3.246

4.  MicroRNA-326 Upregulates B Cell Activity and Autoantibody Production in Lupus Disease of MRL/lpr Mice.

Authors:  Yuan Xia; Jin-Hui Tao; Xuan Fang; Nan Xiang; Xiao-Juan Dai; Li Jin; Xiao-Mei Li; Yi-Ping Wang; Xiang-Pei Li
Journal:  Mol Ther Nucleic Acids       Date:  2018-03-01       Impact factor: 8.886

5.  A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.

Authors:  Rachael D Wright; Fariba Bannerman; Michael W Beresford; Louise Oni
Journal:  BMC Nephrol       Date:  2020-06-30       Impact factor: 2.388

6.  Double Negative B Cell Is Associated With Renal Impairment in Systemic Lupus Erythematosus and Acts as a Marker for Nephritis Remission.

Authors:  Xujie You; Ruijun Zhang; Miao Shao; Jing He; Jiali Chen; Jiajia Liu; Xia Zhang; Xu Liu; Rulin Jia; Xiaolin Sun; Zhanguo Li
Journal:  Front Med (Lausanne)       Date:  2020-04-07

7.  Autoimmune rheumatic diseases: One or many diseases?

Authors:  Haralampos M Moutsopoulos
Journal:  J Transl Autoimmun       Date:  2021-10-28

8.  Low copy numbers of complement C4 and homozygous deficiency of C4A may predispose to severe disease and earlier disease onset in patients with systemic lupus erythematosus.

Authors:  M Jüptner; F Flachsbart; A Caliebe; W Lieb; S Schreiber; R Zeuner; A Franke; J O Schröder
Journal:  Lupus       Date:  2017-10-19       Impact factor: 2.911

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.